摘要
目的:比较米氮平和文拉法辛治疗首发抑郁症患者的疗效及安全性。方法:66例首发抑郁症患者随机分为米氮平组(n=32)和文拉法辛组(n=34),治疗8周。以汉密尔顿抑郁量表(HAMD)与治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:治疗后两组均有显著疗效,两组疗效差异无显著性。结论:米氮平和文拉法辛均可以作为抑郁症的首选治疗药物。
Objective： compare the efficacy and safety of mirtazapine and venlafaxine in the treatment of first-onset depression. Method： 66 patients with first-onset depression were randomly assigned two groups each of which received mirtazapine（n = 32） or venlafaxine treatment（n = 34） for 8 weeks. Hamilton depression rating scale （HAMD） and treatment emergent symptoms scale were used to assess efficacy and side effects. Results： The two groups showed high curative effect rate after the treatment,but no significant difference was found between the two groups. Conclusion： mirtazapine and venlafaxine can be applied as first-line drugs in treatment of depression.
出处
《临床精神医学杂志》
2010年第4期270-271,共2页
Journal of Clinical Psychiatry
关键词
抑郁症
米氮平
文拉法辛
depression
mirtazapine
venlafaxine
